AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Studies support Targretin's activity in NSCLC.
2004 MAY 6 - (NewsRx.com & NewsRx.net) -- Three separate studies by Ligand Pharmaceuticals, Inc., (LGND) scientists presented at the 95th annual meeting of the American Association of Cancer Research (AACR) support enhanced activity of chemotherapeutic agents in combination with Targretin (bexarotene) in non-small cell lung cancer (NSCLC) and a novel activity of Targretin preventing or reversing acquired tumor cell resistance to paclitaxel (Taxol) in NSCLC and advanced human breast cancer cell lines.
"The results presented at AACR provide new insights into the mechanism of action of Targretin in NSCLC by uncovering synergistic activity of Targretin together with different commonly used chemotherapeutic agents and by characterizing a unique action of Targretin to prevent or reverse acquired drug resistance to Taxol and other chemo agents," said Andres Negro-Vilar, MD, PhD, Ligand's executive vice president for research and development and chief scientific officer. "We believe these insights on mechanism are particularly relevant to our combination studies SPIRIT I and II (frontline) and our ongoing and planned studies in second and third line."
Taxol is an important anticancer agent for the treatment of NSCLC, breast, and many other types of cancer. Its extended utility, however, is limited by the development of acquired drug resistance by tumor cells, a phenomenon that also affects other taxanes and chemotherapeutic agents. The potential role of Targretin in preventing or reversing Taxol resistance is addressed in a another study (abstract #2144).
Ligand's scientists developed a model of Taxol-resistance NSCLC cell lines and demonstrated that using different regimens of sequential and/or continuous combined treatment of Taxol with Targretin resulted in the prevention and/or reversal of acquired resistance to Taxol. Resistant NSCLC tumor cells not only did not respond to additional Taxol treatment but also showed that the acquired resistance also affected other commonly used chemo agents such as vincristine and doxorubicin. All these agents have been shown to be substrates for the P-glycoprotein pump.
Development of resistance was confirmed by the increased expression of the multidrug resistance gene MDR-1 and by the increased efflux activity of PgP. The results further showed that Targretin prevented resistance and cross-resistance by suppressing the expression of the ...
- Ligand's Targretin Combined With Taxol Prevents and Overcomes Acquired Taxol...
- Press release article from: Business Wire April 8, 2003 700+ words
...after multiple exposures, the Targretin / Taxol combination either significantly...multiple exposures, both the Targretin / Taxol and Targretin / doxorubicin...alone, Targretin alone, or the Targretin / Taxol combination. Tumor growth was...
- New Findings Presented at AACR Show Ligand's Targretin Synergizes with...
- Press release article from: Business Wire March 29, 2004 700+ words
...continuous combined treatment of Taxol with Targretin resulted in the prevention...In vivo studies showed that Targretin and Taxol combined treatment provided...and that the combination of Taxol plus Targretin but not Taxol alone significantly...
- Studies support Targretin's activity in NSCLC.
- Newspaper article from: Cancer Weekly May 4, 2004 700+ words
...continuous combined treatment of Taxol with Targretin resulted in the prevention...In vivo studies showed that Targretin and Taxol combined treatment provided...and that the combination of Taxol plus Targretin but not Taxol alone significantly...
- Ligand Completes Patient Enrollment in Second Pivotal Study of Targretin...
- Press release article from: Business Wire September 18, 2003 700+ words
...showed that combining Targretin with Taxol(R) (paclitaxel...acquired resistance to Taxol in human breast cancer...results suggest that Targretin may sensitize cancer...hypothesized that Targretin may prevent Taxol resistance by influencing...
- Targretin Fails to Meet Primary or Secondary Endpoints in Pivotal Trials for...
- Press release article from: Business Wire March 28, 2005 700+ words
...its two pivotal Phase III studies of Targretin(R) (bexarotene) capsules in front...were designed to evaluate whether adding Targretin to front-line cisplatin/vinorelbine...chemotherapy alone or in combination with Targretin capsules. SPIRIT II enrolled patients...
- Targretin--R-- Capsules May Increase Survival in Patients with Non-Small Cell...
- Press release article from: Business Wire August 14, 2000 700+ words
...follow-up study results suggesting that Targretin(R) (bexarotene) capsules in combination...a growing body of data that suggests Targretin therapy may, in some solid tumors...results from a Phase I/II trial of Targretin with a cisplatin-based chemotherapy...
- Targretin Capsules Shows Activity in Clinical Trials in Patients with Non-Small...
- Press release article from: Business Wire May 23, 2000 700+ words
...abstracts on study results suggesting that Targretin(R) (bexarotene) capsules may delay...lung cancer (NSCLC) and showing that Targretin capsules provide a convenient, oral...Phase II trial, the administration of Targretin capsules, a novel synthetic retinoid...
- Targretin(R) Capsules Show Positive Results in Moderate to Severe Plaque...
- Press release article from: Business Wire May 3, 2000 700+ words
...results of Phase II clinical trials of Targretin(R) capsules to treat patients with...two Phase II-III clinical trials of Targretin(R) capsules to treat patients with...assessment method for evaluating CTCL. Targretin capsules therapy was approved by the...
Source: HighBeam Research, Studies support Targretin's activity in NSCLC.